Graphite founder takes drug to recently-launched Kamau Therapeutics for a second chance: #ASH23
SAN DIEGO — After Graphite Bio’s implosion, Matthew Porteus wants to do things differently.
The Stanford researcher’s stint at the biotech ended with Graphite selling itself in a reverse merger. The startup fell apart after the first patient in its lead program, a gene editing sickle cell therapy called nula-cel, developed a serious side effect and the company shelved the drug.
Now, nula-cel is getting another chance at Porteus’ new company, Kamau Therapeutics, which is presenting extended follow-up data on that patient at this year’s American Society of Hematology meeting. Kamau emerged from stealth last week, and Porteus, who is acting CEO until a full-time leader is hired, says he’s learned from Graphite’s mistakes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
